Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22760
Title: Ambulatory oxygen in fibrotic ILD: a pilot, randomised, triple-blinded, sham-controlled trial.
Authors: Khor, Yet H;Holland, Anne E;Goh, Nicole S L;Miller, Belinda R;Vlahos, Ross;Bozinovski, Steven;Lahham, Aroub;Glaspole, Ian;McDonald, Christine F
Affiliation: Department of Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia
Department of Medicine, Monash University, Melbourne, Australia
School of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
Department of Physiotherapy, Alfred Health and Monash University, Melbourne, Australia
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia
School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia
Issue Date: 27-Feb-2020
EDate: 2020-02-27
Citation: Chest 2020; online first: 27 February
Abstract: Despite a lack of evidence, ambulatory oxygen therapy is frequently prescribed for patients with interstitial lung disease (ILD) and exertional desaturation. Patients often prefer portable oxygen concentrators to oxygen cylinders. This study aimed to examine the feasibility of conducting a clinical trial of ambulatory oxygen delivered via portable concentrators in patients with ILD. In this randomised, triple-blinded, sham-controlled trial, 30 participants with ILD and isolated exertional desaturation to <90% on 6-minute walk tests were randomised to 12-week ambulatory oxygen or air delivered via portable concentrators, with assessments performed at baseline and Weeks 4, 12 and 18. Primary outcomes were trial feasibility and the change in 6-minute walk distance (6MWD) on room air at Week 12. Study recruitment was completed within 18 months, with six withdrawals. Participant blinding was successful, with the Bang's Blinding Index being 0 (95% CI -0.40, 0.40) for the oxygen group and 0 (-0.42, 0.42) for the sham group. There was no significant difference in 6MWD between groups at Week 12 (mean difference of -34m [95% CI: -105, 36], p = 0.34). For secondary outcomes, compared to the sham group, the oxygen group had a significantly higher Leicester Cough Questionnaire psychological domain score, indicating better cough-related quality of life (mean difference of 0.9 [95% CI: 0.2, 1.6], p = 0.01), but a shorter duration of moderate-to-vigorous activities (mean difference of -135 [95% CI: -267, -3], p = 0.04) at Week 12. Based on the results of this pilot study, a definitive randomised controlled trial with a longer intervention duration is warranted to clarify therapeutic impacts of ambulatory oxygen in patients with ILD.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22760
DOI: 10.1016/j.chest.2020.01.049
ORCID: 0000-0002-5434-9342
0000-0003-2061-845X
0000-0003-2065-4346
0000-0001-6481-3391
PubMed URL: 32113924
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.